1. Home
  2. TWIN vs CHRS Comparison

TWIN vs CHRS Comparison

Compare TWIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$18.62

Market Cap

269.7M

Sector

Industrials

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.66

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWIN
CHRS
Founded
1918
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
269.7M
296.8M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
TWIN
CHRS
Price
$18.62
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
51.5K
1.3M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
0.98%
N/A
EPS Growth
N/A
472.00
EPS
1.76
N/A
Revenue
$340,738,000.00
N/A
Revenue This Year
$10.79
$73.08
Revenue Next Year
$8.43
$30.94
P/E Ratio
$10.40
N/A
Revenue Growth
15.45
N/A
52 Week Low
$6.90
$0.72
52 Week High
$19.67
$2.62

Technical Indicators

Market Signals
Indicator
TWIN
CHRS
Relative Strength Index (RSI) 55.16 42.56
Support Level $14.38 $1.55
Resistance Level $18.83 $1.80
Average True Range (ATR) 1.25 0.11
MACD 0.11 -0.02
Stochastic Oscillator 68.59 6.93

Price Performance

Historical Comparison
TWIN
CHRS

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: